Is Xencor (XNCR) Undervalued After Its Recent Share Price Surge?
Xencor (XNCR) has seen a significant surge in its share price recently, with a 32.03% return over the last 30 days and 262.90% over the past year. Despite this, the company is still considered 5.3% undervalued against a fair value of $28.50, driven by its robust XmAb platform and efficient clinical trial strategy. However, potential risks include increased competition in TL1A programs and possible delays or underwhelming data from key trials like XmAb942 or XmAb412.
103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC
DCF Advisers LLC recently acquired 103,736 shares of Xencor, Inc. (NASDAQ:XNCR) during the second quarter, establishing a new position valued at approximately $1.67 million. Other institutional investors also adjusted their holdings in the biopharmaceutical company, which recently reported better-than-expected quarterly revenue of $51.22 million and an adjusted loss of $0.29 per share. Despite trading near its 12-month high, analysts maintain an overall "Hold" rating for Xencor with an average price target of $24.86.
Xencor stock hits 52-week high at 26.18 USD
Xencor Inc.'s stock reached a 52-week high of $26.18 USD, reflecting a significant 238.35% increase over the past year and substantial year-to-date and six-month returns. The biotechnology company, with a market capitalization of $1.93 billion, is advancing its pipeline, including presenting Phase 1 study results for its XmAb819 antibody at the European Society of Medical Oncology Congress 2026. Despite its strong performance, an InvestingPro analysis suggests the stock is overvalued relative to its Fair Value.
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline?
Xencor, Inc. reported a mixed financial performance for Q2 2026, showing a reduced net quarterly loss of US$21.73 million, yet an expanded net loss of US$150.65 million for the first half of the year. This disparity suggests uneven cost management, prompting investors to consider whether future clinical milestones for its TL1A-focused pipeline, particularly XmAb942, can offset widening losses and potential dilution risks from ongoing high R&D spending. The company's investment narrative projects significant revenue and earnings growth by 2029, with some analysts presenting even more optimistic forecasts.
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline?
Xencor, Inc. reported a narrower net loss of US$21.73 million for Q2 2026 but a wider net loss of US$150.65 million for the first half of 2026. This mixed financial performance highlights the company's uneven cost profile and continued lack of profitability, despite ongoing R&D investment in its TL1A-focused pipeline. Investors face the challenge of balancing future clinical milestones against the risk of capital raising and dilution due to widening year-to-date losses.
Analysts' Revenue Estimates For Xencor, Inc. (NASDAQ:XNCR) Are Surging Higher
Xencor, Inc.'s revenue estimates have been significantly upgraded by analysts, signaling increased optimism for the company's future performance. This positive revision comes despite the company not having current revenues, as analysts anticipate strong growth. The upgraded forecasts suggest a bright outlook for Xencor, Inc. in the coming years.
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts
Industry analysts have significantly upgraded their revenue forecasts for Xencor, Inc. (NASDAQ:XNCR) for 2026, with the consensus estimate now at US$144 million, a 37% increase from the previous year's sales. This revised outlook suggests a much more bullish perspective on the company's prospects, forecasting an 88% annualized growth rate, outperforming the broader industry's 23% annual growth expectation. Despite the upgraded revenue targets, the consensus price target remains unchanged at US$29.00.
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts
Industry analysts have significantly upgraded their revenue forecasts for Xencor, Inc. (NASDAQ:XNCR) for 2026, projecting a 37% increase in sales to US$144 million. This increased optimism also suggests that Xencor is expected to grow much faster than the broader industry. Shareholders have already seen a 12% share price gain in the last week, following the positive outlook.
(XNCR) as a Liquidity Pulse for Institutional Tactics
This article analyzes Xencor Inc. (NASDAQ: XNCR) based on AI models, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with a multi-timeframe signal analysis. The analysis is presented by Stock Traders Daily's Quantitative Research Desk.
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
Several biotech stocks, including BioVie Inc. (BIVI), Xencor Inc. (XNCR), Alto Neuroscience Inc. (ANRO), Haemonetics Corporation (HAE), and ACADIA Pharmaceuticals Inc. (ACAD), reached 52-week highs on August 12, 2026. These gains were propelled by positive catalysts such as promising clinical trial results, strong quarterly financial reports, and advancements in drug pipelines. The article details the specific developments and financial performance driving each company's stock surge.
Xencor stock hits 52-week high at 21.99 USD
Xencor Inc. (XNCR) has reached a new 52-week high of $21.99, demonstrating a 41% year-to-date return and a 178.71% increase over the past year, reflecting strong investor confidence in the biotechnology company. This growth is attributed to its innovative work in engineered monoclonal antibodies for cancer and autoimmune diseases, with recent positive analyst revisions and upcoming presentation of Phase 1 study results for XmAb819 at ESMO 2026. Despite its strong performance, InvestingPro data suggests the stock might be overvalued relative to its Fair Value.
Xencor (XNCR) Could Be 24% Below Fair Value On Narrower Quarterly Loss
Xencor (XNCR) recently reported a narrower quarterly net loss, reinforcing positive sentiment and leading to significant share price returns over the last month and year. Despite negative 3- and 5-year returns, the company is considered 24.3% undervalued with a fair value of $28.50 compared to its current price of $21.58, driven by expectations of pipeline expansion and future earnings. However, a cross-check of its P/S ratio at 15.3x sales suggests potential valuation risk, trading above the industry average.
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results
Xencor, Inc. (NASDAQ:XNCR) recently released a strong quarterly report, with revenue significantly beating expectations and losses being smaller than predicted. This positive performance has led analysts to upgrade their revenue estimates for 2026 and reduce loss estimates, though the consensus price target remains unchanged. Despite the wide range in analyst price targets, Xencor's revenue growth is now projected to accelerate substantially faster than its historical performance and the wider industry.
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results
Xencor, Inc. recently reported strong quarterly results, with revenue significantly beating expectations and losses being smaller than predicted. This led analysts to upgrade revenue estimates and reduce loss forecasts for 2026, anticipating substantial growth compared to the broader industry. Despite the positive outlook, the consensus price target remained unchanged, indicating continued analyst concern about ongoing losses.
Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside
Xencor, Inc. (XNCR) has seen its average 12-month price target raised from $28.75 to $29 by 12 analysts, implying a 45% potential upside from its Aug. 6 closing price. The consensus rating for the stock remains "Buy" among 14 analysts, with 12 recommending a Buy and 2 a Hold.
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Xencor (NASDAQ:XNCR) from "strong sell" to "hold" after the company reported better-than-expected quarterly results, including a smaller loss per share and significantly higher revenue than anticipated. Despite the upgrade and several bullish analyst price targets, the broader analyst consensus remains a "hold" due to ongoing profitability concerns, with analysts expecting a full-year loss. Xencor's stock has seen positive movement, trading up 4.0% and showing strong performance relative to its 52-week lows, while institutional investors have adjusted their positions.
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages
Xencor, Inc. (NASDAQ:XNCR) has received a consensus "Hold" recommendation from brokerages, with nine firms providing ratings. The biopharmaceutical company recently reported a quarterly loss of $0.29 per share, exceeding analyst estimates, and saw its revenue increase by 17.4% year over year. Several institutional investors have also significantly increased their holdings in Xencor.
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
Xencor, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting advancements in its oncology and autoimmune disease pipelines. Key updates include the progress of XmAb819 in clinical trials for various cancers, the advancement of XmAb942 and XmAb412 for inflammatory bowel disease, and an anticipated cash runway through 2028. The company also noted a significant increase in revenue for the full year 2025 and a reduced net loss compared to the previous year.
Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?
Xencor, Inc. reported mixed Q2 and half-year 2026 results, with a narrowing net loss for the quarter but a widened net loss for the first six months. This financial divergence highlights the impact of R&D spending on the company's profile and prompts a re-evaluation of its investment narrative, particularly concerning funding needs and spending discipline. The article emphasizes that while the Q2 improvement is positive, the higher year-to-date deficit keeps the focus on funding and trial execution risks related to Xencor's key clinical programs like XmAb942 and XmAb412.
Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings
Xencor (NASDAQ:XNCR) shares reached a new 52-week high after reporting better-than-expected quarterly earnings and revenue. The biopharmaceutical company posted an EPS of $(0.29), significantly beating the consensus estimate of $(0.80), and revenue of $51.22 million, surpassing expectations. Despite remaining unprofitable with a negative net margin, analysts maintain a "Moderate Buy" rating with an average price target of $24.62, and several institutional investors have increased their positions.
Xencor Inc 2Q 2026: Revenue $51.22M, EPS ($0.29) — 10-Q Summary
Xencor Inc reported its second-quarter 2026 results, showing a revenue increase to $51.22 million from $43.61 million year-over-year. Despite the revenue growth, the company posted a net loss of ($21.73 million) and a diluted loss per share of ($0.29). Key drivers included higher royalties from Ultomiris and Monjuvi, the resolution of a royalty dispute, and advancements in multiple clinical programs.
Xencor Reports Second Quarter 2026 Financial Results
Xencor, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in its clinical pipeline and strategic partnerships. Key updates include planned presentations for XmAb819 at ESMO 2026, continued enrollment for XmAb942 in the XENITH-UC study, and the initiation of a first-in-human study for XmAb412. The company also announced a $105 million settlement with Alexion and a $10 million milestone payment from Zenas BioPharma, projecting sufficient cash resources to fund operations through 2028.
Xencor (NASDAQ: XNCR) nets $105M Alexion settlement as Q2 2026 loss hits $21.7M
Xencor (NASDAQ: XNCR) reported a Q2 2026 net loss of $21.7 million, narrowing from $30.8 million in Q2 2025, on revenues of $51.2 million. The company also announced a post-quarter-end settlement with Alexion for $105 million, resolving a U.S. royalty dispute related to Ultomiris while retaining ex-U.S. royalty rights. Xencor's cash and marketable securities stood at $486.4 million as of June 30, 2026, and the company projects these funds to cover operations for at least 12 months.
Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS
Xencor (NASDAQ:XNCR) reported quarterly EPS of ($0.29), significantly beating analyst expectations of ($0.80) by $0.51, despite maintaining a negative net margin. The biopharmaceutical company's shares traded near $19.84, close to its 52-week high, with major institutional investors like Goldman Sachs and JPMorgan increasing their holdings. Analysts generally have a "Moderate Buy" rating for XNCR, with an average price target of $24.25.
Xencor, Inc.: Xencor Reports Second Quarter 2026 Financial Results
Xencor, Inc. announced its second quarter 2026 financial results, highlighting progress in its clinical pipeline with key milestones expected for XmAb819, XmAb942, and XmAb412. The company also reported on recent partnership developments, including a $105 million settlement from Alexion and a $10 million milestone payment from Zenas BioPharma. Xencor expects to end 2026 with $420 million to $440 million in cash, sufficient to fund operations through 2028.
Xencor, Inc. Stock 12‑Month Price Target Raised to $28.5, Implies 44% Upside
Xencor, Inc.'s stock has seen its average 12-month price target raised from $28.33 to $28.5 by 12 analysts, with individual forecasts ranging from $14 to $44 per share. This new target implies a potential upside of approximately 44% based on the August 5th closing price. The consensus rating from 14 analysts remains a "Buy," with 12 recommending Buy and 2 recommending Hold.
Xencor: Q2 Earnings Snapshot
Xencor Inc. reported a Q2 loss of $21.7 million, or 29 cents per share, which surpassed Wall Street's expectation of an 82-cent loss per share. The biotech company also posted revenue of $51.2 million, significantly beating the Street forecast of $11.7 million. These results were generated using data from Zacks Investment Research.
Xencor faces earnings test after revenue miss rocks biotech By Investing.com
Xencor, a clinical-stage biopharmaceutical company, is set to report its second-quarter results as investors seek signs of revenue recovery after a significant first-quarter miss. Analysts anticipate a loss of $0.81 per share on $17.51 million in revenue, an improvement from the previous quarter but still a substantial year-over-year decline. The company's revenue heavily relies on lumpy partnership milestone payments, making their timing critical, alongside pipeline progress and cash runway.
Xencor (XNCR) Could Be 29% Undervalued Following Its Sharp Single Day Move
Xencor (XNCR) recently experienced a sharp single-day stock move
(XNCR) Risk Channels and Responsive Allocation
This article analyzes Xencor Inc. (XNCR) using AI models to identify strong sentiment across all horizons, supporting an overweight bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis for support and resistance levels. The report highlights compelling upside potential for XNCR due to the absence of resistance levels above its current price.
XNCR|Xencor Inc|Price:20.220|Chg%:-1.270
This article provides a comprehensive stock analysis of Xencor Inc (XNCR), highlighting its stable fundamentals, significant growth potential, and "fairly valued" status. It notes high institutional ownership and multiple analyst "Buy" ratings with a target price of $29.64. The company, a clinical-stage biopharmaceutical firm, is developing engineered antibodies for cancer and autoimmune diseases, with 20+ candidates in clinical development.
Xencor Secures Ultomiris Royalty Settlement Payment
Xencor announced a settlement agreement with Alexion Pharma International Operations regarding U.S. royalties on Ultomiris, securing $105 million in two installments. This agreement eliminates Alexion’s future U.S. royalty obligations while preserving ex-U.S. royalties. The capital effectively replaces anticipated U.S. royalty income through 2028, extending Xencor's operating runway to the same year.
Vanguard Capital Management (XNCR) discloses 3.8M-share, 5.13% stake in Xencor
Vanguard Capital Management has disclosed a 5.13% passive stake in Xencor Inc. (XNCR), holding 3,810,823 shares of common stock. This ownership is reported across various Vanguard funds and managed accounts, with Vanguard exercising sole voting power over 532,021 shares and sole dispositive power over all 3,810,823 shares. The filing, a Schedule 13G, indicates that the stake is for investment purposes and not intended to influence company control.
Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR
Several biotech stocks, including Corcept Therapeutics (CORT), Neogen Corporation (NEOG), First Tracks Biotherapeutics (TRAX), Baxter International (BAX), and Xencor Inc. (XNCR), reached 52-week highs on July 30, 2026. These gains were primarily driven by positive quarterly financial results, significant progress in clinical trials, or strategic business announcements like settlement agreements and divestitures. The companies reported strong revenues, advanced drug candidates, and in some cases, provided optimistic future guidance.
Xencor (XNCR) Reiterated by Wedbush -- Rating Maintained at Outp
Wedbush has reiterated its Outperform rating for Xencor (XNCR) with a maintained price target of $26.00, reflecting confidence in its future performance. However, GuruFocus's GF Value™ indicates the stock is significantly overvalued at $19.91 compared to its intrinsic value of $9.13, and its GF Score™ of 46/100 points to below-average performance, particularly in profitability and growth. Mixed guru activity and insider selling further complicate the investment outlook, urging caution for potential investors.
XNCR|Xencor Inc|Price:21.470|Chg%:+1.940
Xencor Inc (XNCR) shows promising fundamentals and growth potential, despite recent weak technical performance. The stock is considered fairly valued within the Biotechnology & Medical Research industry, with analysts generally rating it a "Buy" and expecting an upward trend in the medium term. Major institutional investors hold significant stakes in the company, which specializes in developing engineered antibodies for cancer and autoimmune diseases.
Xencor Shares Rise After Settlement Deal With Alexion
Xencor shares increased following a settlement deal with Alexion, a subsidiary of AstraZeneca. The agreement resolves litigation related to Xencor's bispecific antibody, XmAb11516, which targets the C5 protein, the same target as Alexion's Soliris and Ultomiris. Under the deal, Xencor will pay Alexion royalties on global sales of XmAb11516, and Alexion will grant Xencor a non-exclusive license for several Alexion patents.
Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?
Xencor (NASDAQ:XNCR) shares recently reached a new 52-week high of $21.64, closing at $21.32, marking a 10.1% gain for the session. Despite this stock performance, the company reported significant weakness in its latest quarter, with an EPS loss of $1.71 against an expected $0.75 and revenue of $4.52 million compared to estimates of $27.86 million, representing an 86.2% year-over-year decline. Analysts hold a "Moderate Buy" consensus rating with an average target price of $24.25, while institutional investors have shown increased interest, boosting their stakes in the company.
Xencor stock hits 52-week high at 21.34 USD By Investing.com
Xencor Inc.'s stock has reached a new 52-week high of $21.34, trading at $21.40, marking a significant recovery and a 154.93% surge over the past year. This growth is attributed to the biotechnology company's focus on developing engineered monoclonal antibodies for cancer and autoimmune diseases, though InvestingPro suggests the stock may be overvalued. The company is set to report earnings soon and will present Phase 1 study results for its XmAb819 antibody at the ESMO Congress 2026.
Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)
Xencor (XNCR) shares rose after settling a royalty dispute with Alexion Pharma, a subsidiary of AstraZeneca (AZN). The dispute was related to Ultomiris, a rare disease therapy. Xencor had previously lowered its operating outlook in March due to this issue.
Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)
Wedbush has reiterated an "outperform" rating for Xencor (NASDAQ:XNCR) and maintained a $26 price target, suggesting a 30.4% upside. Despite this positive outlook, the biopharmaceutical company reported weak Q1 earnings, missing revenue and EPS estimates significantly. Analyst sentiment remains mixed, with a "Moderate Buy" consensus target of $24.25.
Xencor (NASDAQ: XNCR) to receive $105M, ending U.S. Ultomiris royalties
Xencor, Inc. has settled a commercial dispute with Alexion Pharma International Operations Limited regarding U.S. royalties on Ultomiris, agreeing to receive $105 million in two equal payments. This settlement concludes Alexion's obligation to pay U.S. royalties, while ex-U.S. royalties remain unaffected. The influx of capital is expected to fund Xencor's research and development programs and operations through 2028.
Xencor stock hits 52-week high at 21.34 USD
Xencor Inc. (XNCR) stock reached a 52-week high of $21.34, trading at $21.40, marking a significant recovery from its $6.92 low and reflecting a 154.93% surge over the past year. This growth is attributed to investor confidence in its innovative pipeline of engineered monoclonal antibodies for cancer and autoimmune diseases. Despite the stock trading near its high, InvestingPro analysis suggests it may be overvalued relative to its Fair Value estimate, with earnings expected in six days.
Xencor Reaches $105 Million Ultomiris Royalty Settlement With Alexion; U.S. Royalties End
Xencor has settled a dispute with Alexion over U.S. royalties for Ultomiris, securing a $105 million payment. This settlement, to be paid in two installments, concludes Alexion's obligation for U.S. sales royalties, though ex-U.S. royalties will continue. The agreement became effective on July 29, 2026.
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor, Inc. announced an agreement with Alexion Pharma International Operations Limited to resolve a commercial dispute regarding U.S. royalties for Ultomiris. Xencor will receive $105 million in two equal payments, removing Alexion's future obligation for U.S. royalties while ex-U.S. royalties remain unchanged. This resolution extends Xencor's operating runway estimate through 2028.
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor will receive $105 million from Alexion to resolve a dispute regarding U.S. royalties for Ultomiris®. The payment will be made in two equal installments, with the first in August 2026 and the second a year later. This resolution extends Xencor's operating runway through 2028, while ex-U.S. royalties for Ultomiris® remain unchanged.
Xencor (XNCR) Expected to Post Earnings on Wednesday
Xencor (XNCR) is set to release its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts forecasting a loss of $0.84 per share and revenue of $18.8890 million. The company significantly missed prior quarter estimates, reporting a $1.71 loss per share on $4.52 million in revenue, an 86.2% decrease year over year. Despite recent stock volatility and mixed analyst ratings ranging from "Strong Sell" to "Buy," the consensus remains a "Moderate Buy" with an average price target of $24.25.
Xencor Inc (XNCR) Institutional Confidence
Xencor Inc (XNCR) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The overall institutional shareholding proportion decreased by 6.84% quarter-over-quarter to 119.03%. ETHSX is the largest institutional shareholder, holding 0.75% of outstanding shares, despite a 2.60% decrease in its holdings.
Xencor Inc (XNCR) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Xencor Inc (XNCR), detailing its current valuation score of 6.68, which ranks it 288 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -8.70 and notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The report indicates a recent update to the score on July 28, 2026.
Xencor Inc (XNCR) Cash Flow
This article presents the detailed cash flow statements for Xencor Inc (XNCR), breaking down operating, investing, and financing activities across various quarterly and annual periods. It includes financial figures for net income, capital expenditures, and changes in working capital, allowing users to analyze the company's financial health. The page also offers FAQs explaining key cash flow concepts and how Xencor's figures relate to these definitions.
